- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- November 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- June 2024
- 200 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- August 2024
- 150 Pages
Global
From €2651EUR$2,789USD£2,227GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- February 2024
- 180 Pages
Global
From €4724EUR$4,969USD£3,968GBP
- Report
- August 2024
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- April 2022
- 136 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Synovial sarcoma is a rare type of cancer that affects the soft tissues of the body. It is most commonly found in the arms and legs, but can also occur in other parts of the body. Treatment for synovial sarcoma typically involves a combination of chemotherapy, radiation therapy, and surgery. Oncology drugs are used to treat cancer, and the market for synovial sarcoma drugs is a subset of the larger oncology drug market.
The synovial sarcoma drug market is highly competitive, with a number of companies developing and marketing treatments for the disease. Companies in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, and AstraZeneca. These companies are actively researching and developing new treatments for synovial sarcoma, as well as marketing existing treatments. Show Less Read more